Current and Potential Agents for the Treatment of Alopecia Areata
February 2001
in “
Current pharmaceutical design
”
alopecia areata T-cell mediated autoimmune disease hair follicles immunosuppressive agents immunomodulatory contact sensitizers diphenylcyclopropenone squaric acid dibutylester immunosuppression immunomodulation liposomes immunosuppressive cytokines TGF-beta IL-10 apoptosis Fas-FasL system lymphocyte homing receptor CD44v10 gene therapy AA hair loss DPCP SADBE transforming growth factor-beta interleukin-10
TLDR Current and future treatments for alopecia areata focus on immunosuppression, immunomodulation, and protecting hair follicles.
Alopecia areata (AA) was identified as a T-cell mediated autoimmune disease targeting hair follicles. The review discussed current treatments, including immunosuppressive agents and immunomodulatory contact sensitizers like diphenylcyclopropenone and squaric acid dibutylester, evaluating their efficacy and mechanisms. Future treatments might focus on immunosuppression, immunomodulation, or protecting hair follicles from inflammation. Potential approaches included using liposomes for better delivery, applying immunosuppressive cytokines (TGF-beta, IL-10), inhibiting apoptosis via the Fas-FasL system, blocking the lymphocyte homing receptor CD44v10, inducing tolerance, and exploring gene therapy.
